GMP Poland’s Main Pharmaceutical Inspector discusses the dangers behind falsified medicines and the need to control internet pharmacies. She also showcases the great power Poland holds as a manufacturing country with over 200 manufacturers. Can you please start by introducing your organization, Main Pharmaceutical Inspectorate, and explain how it fits within…
law “The advantage of working in a law firm such as SRS Advogados is that it favors specialization in specific legal areas, such as life sciences, in order to meet the client’s needs. The regulatory aspects require study and preparation and are the main aspects of the legal advice of the…
Infarmed Eurico Castro Alves, president of Portugal’s regulatory agency Infarmed, talks about the biggest challenges facing the regulation of health products in the country today, and introduces new initiatives aimed at positioning Infarmed as a regulator of reference worldwide. You have been president of Infarmed since 2012. What have been some…
Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…
partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…
Government Regulation The president of Brancorth Medical talks about the challenges of the start-up med tech scene in Canada, turning innovation into corporate success, and the role of the government in creating the right environment for medical devices companies to flourish in Canada. You started Brancorth Medical in 2011, having spent an…
Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…
Government Regulation You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is a highly developed economy to start with; it is a very established market, with a very good healthcare system. The…
Basic Research A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of biotech to drive the Taiwanese economy in the years to come, and Taiwan’s China connection. Participants: Hsing-Jien Kung, President, National…
Economy “As Mexicans we must be prepared for a new stage of our country’s development”. These were the inspiring words of newly elected Mexican President Peña Nieto, who has promised to transform Mexico into a competitive global power. As the world’s thirteenth largest economy, there is no question that Mexico…
Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics? What is the relevance of the Nordics for the country’s global footprint? Jansen has preserved the cluster model. We…
GGD The co-managing partner of one of Canada’s leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients, and the incentive schemes in place to bring innovation to Canada. What have you seen as the key trends of…
See our Cookie Privacy Policy Here